Current treatment guidelines with approved therapies [70,71,72] indicate the introduction of nucleos(t)ide analog inhibitors of the HBV reverse transcriptase (NUCs) only when chronic HBV infection is accompanied by HBV DNA > 2000 IU/mL and ALT elevation > ULN with the goal of providing long-term therapy for chronic suppression of infection. This evidence concerns the gene GPT and infection.